Arca
Skip to content
Tools
Tools

FKBP1A: Peptidyl-prolyl cis-trans isomerase FKBP1A

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Keeps in an inactive conformation TGFBR1, the TGF-beta type I serine/threonine kinase receptor, preventing TGF-beta receptor activation in absence of ligand.

  • Drugs that act on it: 7
  • Approved: 5
  • In phases 1 to 3: 2
  • Sponsors: 5

Who Is On It, and How Far Along

Every drug ChEMBL records acting on FKBP1A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Other

Approved5

  • Sirolimus
  • Tacrolimus anhydrous
  • Temsirolimus
  • Everolimus
  • Pimecrolimus

Phase 31

  • Zotarolimus

Phase 20

    Phase 11

    • Olocrolimus

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Ceric Sàrl114%
    • Eledon Pharmaceuticals114%

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Small molecule686%
    • Other114%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: FK506-binding protein 1A inhibitor.
    SirolimusApprovedPfizerSmall moleculeInhibitor—409Boxed warning
    Tacrolimus anhydrousApprovedEledon PharmaceuticalsSmall moleculeInhibitor—254Boxed warning
    TemsirolimusApprovedPfizerSmall moleculeInhibitor—164—
    EverolimusApprovedNovartis PharmaceuticalsSmall moleculeInhibitor—159Boxed warning
    PimecrolimusApprovedBausch HealthSmall moleculeInhibitor—4Boxed warning
    ZotarolimusPhase 3Ceric SàrlSmall moleculeInhibitor—9—
    OlocrolimusPhase 1—OtherInhibitor—0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 37 in all, from ClinicalTrials.gov.
    KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast CancerEverolimus, SirolimusPhase 2Not yet recruitingBeijing Konruns Pharmaceutical Co., Ltd.2026-11-16
    Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study.Everolimus, SirolimusPhase 2RecruitingKidney Cancer Research Bureau2026-11-16
    Study of the BioRISE Biolimus Drug-Coated Balloon Versus the SELUTION SLR Sirolimus-Coated Balloon in De Novo Coronary Lesions, With a Single-Arm In-Stent Restenosis Cohort (SUNRISE)SirolimusEarly phase 1Not yet recruitingBiosensors Europe SA2026-11-16
    Effect of Sirolimus on Oocyte Quality in Women Undergoing IVFSirolimus, TemsirolimusPhase 4RecruitingCenter for Human Reproduction2026-11-13
    Lanoracopan to Prevent Acute GVHD Following Haploidentical Peripheral Blood Stem Cell Transplantation: A Prospective Multicenter Single-Arm Exploratory StudyTacrolimus anhydrousPhase 2Not yet recruitingThe First Affiliated Hospital of Soochow University2026-11-09
    Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT)SirolimusNot applicableNot yet recruitingSir Run Run Shaw Hospital2026-11-05
    Efficacy of Fractional Co2 Laser With Topical Tacrolimus 0.1 in the Treatment of Nail PsoriasisTacrolimus anhydrousNot applicableNot yet recruitingCairo University2026-11-05
    Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver MetastasesEverolimus—Enrolling by invitationChiyi Chen2026-11-03
    ADVA ACE Coronary Stent System in Coronary Artery Disease Patients (ADVANCE)EverolimusNot applicableNot yet recruitingAdvanced MedTech Solutions Pvt. Ltd.2026-11-03
    Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized VitiligoTacrolimus anhydrousNot applicableEnrolling by invitationKafrelsheikh University2026-11-02
    Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.Tacrolimus anhydrousPhase 3RecruitingCairo University2026-10-29
    A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.Everolimus, SirolimusPhase 2RecruitingThe First Affiliated Hospital with Nanjing Medical University2026-10-28
    Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800 cGyTacrolimus anhydrousPhase 2Not yet recruitingRonald Paquette2026-10-27
    Microbiota Changes Related to Outcomes in Kidney TransplantationTacrolimus anhydrous—Not yet recruitingHospices Civils de Lyon2026-10-26
    Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis.Tacrolimus anhydrousPhase 3Not yet recruitingCairo University2026-10-23
    Study on the Safety and Efficacy of a Time-of-Day-Based Individualized Tacrolimus Dosing Regimen in Kidney Transplant RecipientsTacrolimus anhydrousPhase 4Not yet recruitingThe First Affiliated Hospital of Guangzhou Medical University2026-10-16
    Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 MedulloblastomaEverolimus, SirolimusPhase 1Not yet recruitingBożenna Dembowska Bagińska2026-10-08
    Laser Atherectomy and Sirolimus-eluting Balloon Angioplasty for CLTISirolimus—Active, not recruitingAttikon Hospital2026-10-05
    Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.TemsirolimusPhase 1 / Phase 2Not yet recruitingUniversity Hospital, Strasbourg, France2026-10-01
    Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet DisorderTemsirolimusPhase 1RecruitingOHSU Knight Cancer Institute2026-09-28
    A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast CancersTemsirolimusPhase 1 / Phase 2Not yet recruitingAdvenchen Pharmaceuticals, LLC.2026-09-10
    A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM CancersTemsirolimusPhase 1 / Phase 2Not yet recruitingAdvenchen Pharmaceuticals, LLC.2026-09-10
    A Single-Center, Retrospective, Propensity-Score-Matched Cohort Study Comparing Drug-Coated Balloon Versus Drug-Eluting Stent for Reducing Immediate Post-Procedural Slow-Flow/No-Reflow in Acute ST-Elevation Myocardial Infarction Patients With High Thrombus BurdenEverolimus, Zotarolimus—RecruitingXijing Hospital2026-09-08
    A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular AnomaliesEverolimus, Temsirolimus—Not yet recruitingNovartis Pharmaceuticals2026-08-17
    Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)TemsirolimusPhase 3RecruitingHannover Medical School2026-07-31
    A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell MalignanciesTemsirolimusPhase 1 / Phase 2RecruitingUmoja Biopharma2026-07-30
    Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy.PimecrolimusNot applicableNot yet recruitingMilosz Pietrus2025-11-20
    The European Bifurcation Club Randomized Trial of Stepwise Provisional Stenting Versus Drug Coated Balloon Therapy for Non-left Main True Coronary BifurcationsZotarolimusNot applicableNot yet recruitingCeric Sàrl2025-02-12
    The Study to Evaluate the Safety and Efficacy of the Onyx FamilyZotarolimus—RecruitingPusan National University Yangsan Hospital2024-08-29
    MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small VesselsZotarolimusNot applicableRecruitingConcept Medical Inc.2024-02-22
    A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK InhibitorPimecrolimusPhase 3Active, not recruitingSanofi2024-02-05
    Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.Pimecrolimus—Active, not recruitingBGP Products Operations GmbH, a Viatris company2023-09-25
    Efficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCTZotarolimus—Active, not recruitingYonsei University2022-04-22
    Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE TrialZotarolimusNot applicableRecruitingYonsei University2022-04-11
    Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)ZotarolimusNot applicableActive, not recruitingElixir Medical Corporation2020-09-24
    Firehawk Rapamycin Target Eluting Coronary Stent North American TrialZotarolimusNot applicableActive, not recruitingShanghai MicroPort Medical (Group) Co., Ltd.2020-09-24
    10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used PimecrolimusPimecrolimus—Active, not recruitingBausch Health Americas, Inc.2007-12-06

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Atopic eczema
    0.60
    Kidney transplant
    0.59
    Liver transplant
    0.59
    Tuberous sclerosis
    0.57
    Graft versus host disease
    0.56
    Neoplasm
    0.55
    Kidney angiomyolipoma
    0.54
    Neuroendocrine neoplasm
    0.53
    Hamartoma
    0.53

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1902, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P62942, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.